Discovery Accelerated

Implementation of Histopathology in Gastrointestinal Clinical Trials

Register Today

Register now and you will receive a link for the recorded event

Event Date

Recorded on April 20, 2021 from 1:30 pm - 2:30 pm EDT

Event Details

Join our Industry Experts For Insights On The Evolution of Histopathology Within Regulatory Clinical Drug Trials.

About This Event

Our expert panel will discuss inflammatory bowel disease and NASH, two therapeutic areas that histopathology uses to determine eligibility and/or primary outcome measures. Our four experts will provide presentations on topics including: 

  • Histopathology as a treatment target in IBD: Aspiration or Reality?
  • Measuring histopathology in IBD trials
  • Histopathology as a treatment target in NASH trials
  • Measuring histopathology in NASH trials

Followed by a panel discussion including questions from our viewers, led by Dr. Vipul Jairath, Chief Medical Officer, Alimentiv Inc.

Expert Panel

Prior to Dr. Rubin’s current appointments, he served for 11 years as Director of Gastroenterology, Hepatology, and Nutrition… Read More

Dr. Pai has lectured nationally and internationally on many aspects of gastrointestinal and hepatic pathology and has directed multiple… Read More

Dr. Harrison is internationally known for studies in hepatitis C and non-alcoholic fatty liver disease with over 200 peer-reviewed… Read More

Dr. Valasek is particularly interested in practical molecular, imaging, and digital pathology techniques (including artificial intelligence)… Read More